| MRSA |
1 |
1 |
| Renal Failure |
0 |
0.99 |
| Acute Kidney Injury |
0 |
0.98 |
| Toxicology |
0 |
0.38 |
| Nephrotoxicity |
0 |
0.37 |
| Otolaryngology |
0 |
0.13 |
| Antibiotics |
0 |
0.08 |
| Clinical Guidelines |
0 |
0.08 |
| Pharmacokinetics |
0 |
0.08 |
| Staphylococcal Infection |
0 |
0.07 |
| Hemodialysis |
0 |
0.06 |
| Renal Disease |
0 |
0.06 |
| Urinary Tract Infection |
0 |
0.06 |
| Dehydration |
0 |
0.05 |
| Hypotension |
0 |
0.05 |
| Kidney |
0 |
0.05 |
| Pneumonia |
0 |
0.05 |
| Staphylococcus Aureus Infection |
0 |
0.05 |
| Students |
0 |
0.05 |
| Tissue |
0 |
0.05 |
| COVID-19 |
0 |
0.04 |
| Patient Safety |
0 |
0.04 |
| Skin and Soft Tissue Infection |
0 |
0.04 |
| ACE Inhibitor |
0 |
0.03 |
| Adverse Effects |
0 |
0.03 |
| Blood |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Child |
0 |
0.03 |
| Dialysis |
0 |
0.03 |
| Diuretics |
0 |
0.03 |
| Endocarditis |
0 |
0.03 |
| Heart Failure (HF) |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Hypertension |
0 |
0.03 |
| Injury |
0 |
0.03 |
| Intravenous |
0 |
0.03 |
| Joint Infection |
0 |
0.03 |
| Meningitis |
0 |
0.03 |
| Meningococcal Disease |
0 |
0.03 |
| Osteomyelitis |
0 |
0.03 |
| Ototoxicity |
0 |
0.03 |
| Pandemic |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Sepsis |
0 |
0.03 |
| South Dakota |
0 |
0.03 |
| Therapeutic Drug Monitoring |
0 |
0.03 |
| Wound Management |
0 |
0.03 |